Ningbo Medicalsystem Biotechnology Co.

Ningbo Medicalsystem Biotechnology Co.

Ningbo Medicalsystem Biotechnology Co. was founded in 2003 by 邹炳德 and listed on the Shenzhen Stock Exchange ChiNext board (300439) in April 2015. The firm is headquartered in Ningbo, China, and describes itself as a national high-tech enterprise focused on in-vitro diagnostics (IVD). Its product range covers biochemistry analyzers, chemiluminescence immunoassay systems, liquid chromatography-tandem mass spectrometers, and VAP lipid subfraction testing. The firm operates through four main segments: laboratory automation, biochemistry analysis, immunology analysis, and mass spectrometry analysis. It produces both instruments and reagents, with over 1,000 diagnostic reagent products and 24 diagnostic instrument registration certificates (per the firm's website). Products are sold to domestic hospitals and testing centers, with growing international distribution in markets such as Southeast Asia and Europe. Named portfolio companies are not publicly disclosed, but the firm lists multiple reference labs and a chain of 10+ clinical testing laboratories under the "Meikang Shengde" brand. Ningbo Medicalsystem maintains R&D facilities in Ningbo, Hangzhou, Changchun, and San Diego, California. The firm was recognized as a specialized "Little Giant" enterprise by Zhejiang Province's Department of Economy and Information Technology in 2024 (per the firm, November 2024). It also operates a reference laboratory, a national gene testing demonstration center, and an advanced mass spectrometry key laboratory. The company runs a philanthropic foundation, the Ningbo Meikang Charity Foundation, with its social responsibility page listing several health-related donation initiatives. Unlike many Chinese diagnostic firms, Ningbo Medicalsystem has built a vertically integrated model — manufacturing both instruments and reagents, operating its own clinical labs, and distributing directly to hospitals. The company's structure as a listed entity means its capital allocation and ownership are publicly reported, offering more transparency than a typical private family office. Succession planning and governance details remain undisclosed.